AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11509678 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine
Number of subjects: 3
Study 9630113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast media
Number of subjects: 210
Study 9630113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic low osmolar contrast media
Number of subjects: 210
Study 9630113 — intervention group
Group type: COMPARATOR
Intervention: Control (Ionic LOCM)
Number of subjects: 210
Study 9630113 — intervention group
Group type: COMPARATOR
Intervention: Control (Nonionic LOCM)
Number of subjects: 210
Study 8172149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 49
Study 8172149 — intervention group
Group type: COMPARATOR
Intervention: ESWL
Number of subjects: 49
Study 29987109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/d
Number of subjects: 18
Study 29987109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/d plus valsartan 160 mg/d
Number of subjects: 18
Study 29987109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29987109 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus valsartan
Number of subjects: 18
Study 26778538 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg
Number of subjects: 106
Study 25019209 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of RSV
Number of subjects: 8
Study 25019209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22987836 — intervention group
Group type: EXPERIMENTAL
Intervention: One hour educational intervention on organ donation
Number of subjects: 184
Study 22987836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study 19826884 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQOL measures used in trials
Number of subjects: 24
Study 18424367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 61
Study 18424367 — intervention group
Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 61
Study 16373894 — intervention group
Group type: EXPERIMENTAL
Intervention: Display group (real-time access to sensor glucose values)
Number of subjects: 91
Study 14662573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with child-oriented toilet training instructions and positive reinforcement (praise for defecating in diaper)
Number of subjects: 406
Study 14662573 — intervention group
Group type: COMPARATOR
Intervention: Control group with child-oriented toilet training instructions
Number of subjects: 406
Study 14662573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 406
Study 14662573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 406
Study 11063393 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthwash, performed twice daily for 3 weeks
Number of subjects: 32
Study 11063393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF/SnF2) mouthwash, performed twice daily for 3 weeks
Number of subjects: 32
Study 8832997 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg, 10 mg, or 15 mg at bedtime
Number of subjects: 19
Study 8832997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8832997 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 19
Study 1571987 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnum system
Number of subjects: 200
Study 1571987 — intervention group
Group type: COMPARATOR
Intervention: Standard system
Number of subjects: 200
Study 1571987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 3906073 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 48
Study 3906073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31348286 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI of TXA and PAI of placebo
Number of subjects: 210
Study 31348286 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI of placebo and PAI of TXA
Number of subjects: 210
Study 31348286 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI of TXA and PAI of TXA
Number of subjects: 210
Study 31348286 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (IAI of placebo and PAI of placebo)
Number of subjects: 210
Study 31348286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of IAI and PAI of TXA
Number of subjects: 210
Study 31348286 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term effects
Number of subjects: 210
Study 30217182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) only
Number of subjects: 66
Study 30217182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation (INS) only
Number of subjects: 66
Study 30217182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) and Nutritional Supplementation (INS)
Number of subjects: 66
Study 27154768 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 213
Study 27154768 — intervention group
Group type: COMPARATOR
Intervention: Community practice control
Number of subjects: 213
Study 25134378 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum procalcitonin (> 0.5 ng/mL)
Number of subjects: 45
Study 25134378 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin > 1.0 ng/mL
Number of subjects: 45
Study 25134378 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum procalcitonin
Number of subjects: 45
Study 21623590 — intervention group
Group type: EXPERIMENTAL
Intervention: SN6AD1 IOL
Number of subjects: 47
Study 21623590 — intervention group
Group type: COMPARATOR
Intervention: ReZoom IOL
Number of subjects: 47
Study 21623590 — intervention group
Group type: EXPERIMENTAL
Intervention: High add power IOLs
Number of subjects: 47
Study 21623590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low add power IOLs
Number of subjects: 47
Study 21623590 — intervention group
Group type: COMPARATOR
Intervention: All IOL types
Number of subjects: 47
Study 21623590 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive optics and aspheric profiles
Number of subjects: 47
Study 21623590 — intervention group
Group type: COMPARATOR
Intervention: All IOLs
Number of subjects: 47
Study 21068427 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihemispheric transcranial direct current stimulation (tDCS) with simultaneous physical/occupational therapy
Number of subjects: 20
Study 21068427 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with simultaneous physical/occupational therapy
Number of subjects: 20
Study 17694946 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable superstructures according to the Marburg double crown system in GAP patients
Number of subjects: 17
Study 17694946 — intervention group
Group type: COMPARATOR
Intervention: Cemented, implant-retained fixed superstructures in periodontally healthy patients
Number of subjects: 17
Study 15619680 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 1053
Study 15619680 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg once weekly
Number of subjects: 1053
Study 12185609 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min exercise at 65% [Vdot]O(2) peak
Number of subjects: 4
Study 12185609 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min immersion in 39 degrees C water
Number of subjects: 4
Study 9466021 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion preceded by normal saline (group P, n = 12)
Number of subjects: 24
Study 9466021 — intervention group
Group type: COMPARATOR
Intervention: Propofol preceded by 2 micrograms.kg‐1 fentanyl (group PF, n = 12)
Number of subjects: 24
Study 7629003 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni-Dur (q24h extended-release theophylline)
Number of subjects: 133
Study 7629003 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur (q12h extended-release theophylline)
Number of subjects: 133
Study 7629003 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni-Dur
Number of subjects: 133
Study 7629003 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 133
Study 7629003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 133
Study 2380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription information leaflets
Number of subjects: 3410
Study 2380943 — intervention group
Group type: COMPARATOR
Intervention: No prescription information leaflets (Control)
Number of subjects: 3410
Study 366143 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg levamisole once weekly
Number of subjects: 0
Study 366143 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg levamisole once weekly
Number of subjects: 0
Study 366143 — intervention group
Group type: COMPARATOR
Intervention: 150 mg levamisole on 3 or 7 consecutive days
Number of subjects: 0
Study 30222208 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 24
Study 30222208 — intervention group
Group type: COMPARATOR
Intervention: Concentric cycling (CON)
Number of subjects: 24
Study 30222208 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2peak improvement
Number of subjects: 24
Study 28623500 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask ventilation without nasal passage occlusion
Number of subjects: 0
Study 28623500 — intervention group
Group type: COMPARATOR
Intervention: Face mask ventilation with nasal passage occlusion (using a swimmer's nose clip)
Number of subjects: 0
Study 26511693 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-screw TBW
Number of subjects: 88
Study 26511693 — intervention group
Group type: COMPARATOR
Intervention: Conventional TBW
Number of subjects: 88
Study 23864786 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5 mg tid)
Number of subjects: 28
Study 22009121 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment group
Number of subjects: 40
Study 22009121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19176454 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy followed by radiotherapy (70 Gy total) after two cycles of cisplatin and 5‐fluorouracil, with a 50% or more reduction in primary tumor size.
Number of subjects: 450
Study 19176454 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy and radiotherapy (60 Gy total) with four cycles of cisplatin and 5‐fluorouracil alternated with radiotherapy (20 Gy during the three 2‐week intervals).
Number of subjects: 450
Study 17245803 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax vaccine
Number of subjects: 1749
Study 15792325 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Case Management Project (ICMP) for Rural Drug Abuse
Number of subjects: 0
Study 15792325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case management)
Number of subjects: 0
Study 12368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 56
Study 12368673 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus propranolol therapy
Number of subjects: 56
Study 12368673 — intervention group
Group type: COMPARATOR
Intervention: GH treatment
Number of subjects: 56
Study 12368673 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 56
Study 12368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination GH plus propranolol therapy
Number of subjects: 56
Study 9614361 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (40 micrograms/kg at 1800 h)
Number of subjects: 17
Study 9614361 — intervention group
Group type: COMPARATOR
Intervention: Control night (untreated)
Number of subjects: 17
Study 8126617 — intervention group
Group type: COMPARATOR
Intervention: Rice-lentil/yogurt/milk diet (group A; n = 26)
Number of subjects: 51
Study 8126617 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula (group B; n = 25)
Number of subjects: 51
Study 7580222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study 7580222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 356916 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone
Number of subjects: 55
Study 356916 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 30232712 — intervention group
Group type: EXPERIMENTAL
Intervention: AUT00063
Number of subjects: 12
Study 30232712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27110643 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian 1600mg
Number of subjects: 0
Study 27110643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24958820 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive OPC
Number of subjects: 181
Study 24958820 — intervention group
Group type: COMPARATOR
Intervention: p16-negative OPC
Number of subjects: 181
Study 24958820 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant progression
Number of subjects: 181
Study 22867787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 0
Study 22867787 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study 20726913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation with 1% sodium hypochlorite (NaOCl) for 1 min (n=35)
Number of subjects: 130
Study 20726913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanal medication with calcium hydroxide [Ca(OH)(2)] for 1 week (n=35)
Number of subjects: 130
Study 20726913 — intervention group
Group type: COMPARATOR
Intervention: Routine cleaning and shaping procedures (n=105)
Number of subjects: 130
Study 20726913 — intervention group
Group type: COMPARATOR
Intervention: Baseline group (n=25)
Number of subjects: 130
Study 18612440 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels measured pre-anesthetic induction and on the 7th postoperative day
Number of subjects: 30
Study 18612440 — intervention group
Group type: EXPERIMENTAL
Intervention: E/Ea ratio measured pre-anesthetic induction and on the 7th postoperative day
Number of subjects: 30
Study 18612440 — intervention group
Group type: COMPARATOR
Intervention: Comparison of NT‐proBNP and E/Ea
Number of subjects: 30
Study 15751152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (10 mg to 20 mg/day subcutaneously)
Number of subjects: 112
Study 15751152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 112
Study 12418582 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (Salm/FP), 50/250 microg bd via Diskus
Number of subjects: 428
Study 12418582 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (12 microg bd) and Budesonide (800 microg bd) via separate Turbuhalers (Form+Bud)
Number of subjects: 428
Study 10756610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained and supported GPs (n = 42) received the programme plus practice-based training and a support telephone call every two weeks.
Number of subjects: 128
Study 10756610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained GPs (n = 43) received the programme plus practice-based training in programme usage.
Number of subjects: 128
Study 10756610 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 43) received the programme with written guidelines only.
Number of subjects: 128
Study 10756610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained and supported GPs
Number of subjects: 128
Study 10756610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 128
Study 10756610 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 128
Study 8777660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of 25% sucrose solution
Number of subjects: 15
Study 8777660 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 15
Study 1920344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 60 or 90 mg/day
Number of subjects: 243
Study 1920344 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 90-240 mg/day
Number of subjects: 243
Study 6136290 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg kg‐1)
Number of subjects: 100
Study 6136290 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.15 mg kg‐1)
Number of subjects: 100
Study 31350681 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging
Number of subjects: 71
Study 31350681 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer navigation
Number of subjects: 71
Study 31350681 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 28973670 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided group (mhealth app)
Number of subjects: 139
Study 28973670 — intervention group
Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 139
Study 28973670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study 26868210 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma diagnosed <1 year or 6 months before the index date
Number of subjects: 0
Study 26868210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator use
Number of subjects: 0
Study 26868210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-asthma drug prescription
Number of subjects: 0
Study 26868210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-asthmatic medication use in Viborg vascular trial
Number of subjects: 0
Study 25785278 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of borderline GDM (lifestyle changes including diet and exercise)
Number of subjects: 22
Study 25785278 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned lifestyle changes (diet and/or exercise)
Number of subjects: 22
Study 25785278 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivators for lifestyle change
Number of subjects: 22
Study 25785278 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to lifestyle change
Number of subjects: 22
Study 25785278 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern after diagnosis
Number of subjects: 22
Study 23058097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to XELOX (oxaliplatin plus capecitabine)
Number of subjects: 0
Study 23058097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to FOLFOX-4 (oxaliplatin plus 5-fluorouracil and folinic acid)
Number of subjects: 0
Study 23058097 — intervention group
Group type: COMPARATOR
Intervention: XELOX (oxaliplatin plus capecitabine)
Number of subjects: 0
Study 23058097 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-4 (oxaliplatin plus 5-fluorouracil and folinic acid)
Number of subjects: 0
Study 20634651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe combined with statins
Number of subjects: 0
Study 20634651 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 20634651 — intervention group
Group type: COMPARATOR
Intervention: Fibrates and niacin
Number of subjects: 0
Study 18637311 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic contrast-enhanced ultrasound assessment
Number of subjects: 50
Study 16037885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclists (ACE and CKMM genotypes)
Number of subjects: 50
Study 16037885 — intervention group
Group type: COMPARATOR
Intervention: Controls (ACE and CKMM genotypes)
Number of subjects: 50
Study 16037885 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners (ACE and CKMM genotypes)
Number of subjects: 50
Study 16037885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclists and Controls (D allele)
Number of subjects: 50
Study 16037885 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners (I allele)
Number of subjects: 50
Study 16037885 — intervention group
Group type: EXPERIMENTAL
Intervention: CKK-MM-NcoI
Number of subjects: 50
Study 12388959 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg every 4 hours
Number of subjects: 42
Study 12388959 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 hours
Number of subjects: 42
Study 12388959 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 42
Study 12388959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10630346 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment twice weekly for 4 weeks
Number of subjects: 75
Study 10630346 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 75
Study 10630346 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 75
Study 7770313 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (25 mg four times daily)
Number of subjects: 37
Study 7770313 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.05 mg four times daily)
Number of subjects: 37
Study 7770313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7770313 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 37
Study 7770313 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 37
Study 2180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 8245
Study 2180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily
Number of subjects: 8245
Study 2180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 8245
Study 2180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 8245
Study 2180268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study 2180268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (all doses)
Number of subjects: 8245
Study 6127906 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2
Study 6127906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol sulphate
Number of subjects: 2
Study 6127906 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 2
Study 30929268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 29